SET AND READY TO UNLEASH THE POTENTIAL OF THE PHARMACIST HEALTH WORKFORCE Government aligns Scope of Practice review with Pharmacists in 2030 report
Filmed in Perth, Western Australia, November 2024
With Associate Professor Fei Sim, National President
Pharmaceutical Society of Australia (PSA)
Last week, Associate Professor Fei Sim the National President of the Pharmaceutical Society of Australia (PSA), the peak body representing 39,000 pharmacists across Australia’s health system, spoke to Australian Health Journal about the release of the Unleashing the Potential of our Health Workforce – Scope of Practice Review. The review and final report sets out to create a clear pathway for health professionals to contribute more to our health system and practice to their full and top of scope.
The report calls for governments to remove the inconsistent barriers that restrict the scope of healthcare professionals, including pharmacists.
PSA National President Associate Professor Fei Sim FPS commended the report’s focus on removing barriers for pharmacists and other healthcare professionals as a critical step towards a more accessible and resilient healthcare system.
“This review confirms PSA’s view that inconsistent regulations, unnecessary restrictions on practice, and siloed workforces are having a negative impact on patient access to quality health care,” Associate Professor Sim said.
“Pharmacists are some of the most accessible healthcare professionals in our communities, yet regulatory barriers continue to limit our ability to provide care when and where our patients need it. The release of this final report is the next step towards breaking down these barriers through a short- and long-term reform agenda, addressing the inefficiencies in our health system.”
Associate Professor Sim said that the report’s recommendations present a genuine opportunity to improve access to health care across Australia.
“There is a clear alignment between Cormack’s recommendations and the actions in PSA’s vision for the pharmacy profession, Pharmacists in 2030. Both present a clear vision for the future that requires collaboration for a health system that works for patients,” Associate Professor Sim said.
“This report recognises the core role of pharmacies and pharmacists as primary healthcare providers and recommends a multidisciplinary approach to patient care.
“In order to make the most of the opportunities presented by the report, we need governments, regulators and health care professionals to work together for a strong, sustainable health system that utilises all health professionals to their full scope.
“I urge governments and stakeholders at all levels to accept and act on the report’s recommendations in full to build a health system ready for the growing health needs of Australians.”
A/Prof Fei Sim served on the Cormack Review’s Expert Advisory Committee, representing the pharmacy profession.
-
Artificial Intelligence (AI) in clinical trials and clinical care
Australian Health Journal today continues a major episode release on Technology Aided Healthcare Delivery, with part 2 on Artificial Intelligence in trials and clinical care. Interviews were captured at AI, Machine Learning & Robotics in Health conference in October organised by Informa Australia.
-
Updated handbook on chronic kidney disease management in primary care
Kidney Health Australia’s latest kidney disease guide for primary care practitioners is expected to be pivotal in slowing down the rates of kidney failure, which have doubled in the past 20 years and if left unchecked will grow by a further 42% by 2030, according to the health charity.
With specific reference to new kidney treatments and culturally safe kidney care for First Nations Australians, the 5th edition of Chronic Kidney Disease (CKD) Management in Primary Care handbook, known as the ‘kidney bible’, is a significant step-up in enabling earlier diagnosis of kidney disease for GPs and other front-line healthcare professionals.
-
Nuclear medicine funding a win for men with prostate cancer
Australian men with higher risk prostate cancer now have access to a nuclear medicine scan to help detect and treat metastatic disease, after it was listed on the Medical Benefits Schedule (MBS) from 1st July 2022.
In 2021 over 18,000 Australian men were diagnosed with prostate cancer, resulting in over 3,000 lives being lost – and making prostate cancer Australia’s second most common cause of cancer death in men.
Australian Health Journal spoke with AANMS President Associate Professor Sze Ting Lee and Dr Geoff Schembri on the MBS listing and the efforts to get it listed.
